Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by gregoooon May 28, 2013 4:51pm
114 Views
Post# 21451785

From BWN MD&A

From BWN MD&A

? The sale of Canaguaro is not done yet and the testing of the 2 new wells has not been done yet-wonder when Omega plans on doing this?

 

Subsequent to March 31, 2013, the Company announced that the sale of its private participating

interest in the Canaguaro Block for gross cash proceeds of US$6,000,000. The sale will provide the

Company with additional working capital and is anticipated to take place by mid-June 2013.

 

These two wells completed drilling operations in March 2013 and the Company believes that

the work commitments for the Block have been met. However, as at the date of this MD&A,

testing of the wells have not been completed and the Company does not have the

information necessary for it to make its option election under the amended agreement.

 

Bullboard Posts